SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MYGN -- Ignore unavailable to you. Want to Upgrade?

To: Israel who wrote (7)2/20/1998 5:43:00 AM
From: Roland Ott  Respond to of 29
 
I believe MYGN is much undervalued at the present moment. I think it will recover by spring, when more biotech events will take place.



To: Israel who wrote (7)2/20/1998 1:47:00 PM
From: Oliver Ruppert  Read Replies (1) | Respond to of 29
 
Issue has been downgraded by a Wall St broker from "strong buy" to "buy". Since then, the price slipped daily...
To tell the truth, I don't know too much about the company, I just hold it because I like their story. Didn't look at any specifics (hopefully i won't be punished for that !)
-oliver



To: Israel who wrote (7)2/21/1998 8:25:00 PM
From: John Prugh  Read Replies (1) | Respond to of 29
 
In recent issue of Forbes (week before last, I think), Michael Gianturco (sp) remarked on his biotech recommendations from the previous year. MYGN was among those, and although it has plummetted a bit (ha ha), he mentions that he thinks that all of his recommendations still represent good buys.
That is a plus for MYGN, especially at its current price, don't you think?
- John


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News